anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
Rituximab was administered weekly x 4 (intravenous 375 mg/m\^2 or subcutaneous equivalent) per institutional standards and placebo orally once daily. Participants took placebo until lack of response at week 13, disease progression, or initiation of a new treatment.
INTRODUCTION: Immunotherapies targeting T cells in solid cancers are revolutionizing clinical treatment. Novel immunotherapies have had extremely limited benefit for acute myeloid leukemia (AML). Here, we characterized the immune microenvironment of t(8;21) AML patients to determine how immune cell infiltration status influenced prognosis.
METHODS: Through multi-omics studies of primary and longitudinal t(8;21) AML samples, we characterized the heterogeneous immune cell infiltration in the tumor microenvironment and their immune checkpoint gene expression. Further external cohorts were also included in this research.
RESULTS: CD8+ T cells were enriched and HAVCR2 and TIGIT were upregulated in the CD34+CD117dim%-High group; these features are known to be associated with immune exhaustion. Data integration analysis of single-cell dynamics revealed that a subset of T cells (cluster_2) (highly expressing GZMB, NKG7, PRF1 and GNLY) evolved and expanded markedly in the drug-resistant stage after relapse. External cohort analysis confirmed that the cluster_2 T-cell signature could be utilized to stratify patients by overall survival outcome.
DISCUSSION: In conclusion, we discovered a distinct T-cell signature by scRNA-seq that was correlated with disease progression and drug resistance. Our research provides a novel system for classifying patients based on their immune microenvironment.
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with polymicrogyria is provided. The seizures associated with polymicrogyria may be tonic, tonic-clonic, atonic, focal seizures with impairment and focal seizures with secondary generalisation. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be selected from the group consisting of: valproic acid, levetiracetam, clobazam, lacosamide, topiramate, lamotrigine and ethosuximide. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein patients diagnosed with polymicrogyria had a decrease in the amount of seizures after dosing with the CBD preparation and concomitant AEDs.
Mitral annular calcification (MAC) is a chronic and degenerative condition involving calcification of the mitral annulus. MAC is a risk factor for coronary artery disease, cardiovascular events, stroke, and cardiovascular death. However, patients with MAC are often asymptomatic. Herein, we present the first case of cardiac tamponade due to infection of MAC in forensic pathology. An 80-year-old woman was found in cardiopulmonary arrest shortly after experiencing fatigue. She was transferred to a hospital, and despite chest compression and ventilation, she was pronounced dead due to no response. Postmortem computed tomography, autopsy, and histological examination showed MAC, abscess formation involving Gram-positive cocci on the MAC, and fistulation of the abscess into the intracardial pericardial cavities, resulting in a massive lethal hemopericardium.
The goal of this study was to investigate the effects of Photobiomodulation therapy (PBMT) on performance, oxygen uptake (VO2 kinetics), and lower limb muscle oxygenation during three successive time-to-exhaustion tests (TTEs) in cyclists. Our study was characterized as a crossover, randomized, double-blind trial (blinding of the cyclists and the researcher responsible for evaluations). All protocols were explained to the participants, who voluntarily provided their consent to participate in the investigation through an informed consent document. This study received approval from the Research Ethics Committee for Human Subjects Studies at the institution where the research was conducted (number 708.362). Inclusion criteria involved cyclists aged 18-30 years, with a competitive history and no history of musculoskeletal injuries in the lower limbs in the last two years. Exclusion criteria included chronic disease, smoking, metabolic disorders, use of steroids in the last six months, chronic disease, physical disabilities, and use of antibiotic drugs in the previous week. The cyclists participating in the present study had \~6.5 years of regular training/competition and no history of lower limb muscular and/or skeletal injuries. Each cyclist visited the laboratory on three occasions. At the first visit, cyclists performed a maximum incremental test and familiarization to three successive TTEs. At the two subsequent visits, participants performed a standard protocol of three successive TTEs at maximal power output (POMAX) with preferred cadence, and PBMT or placebo (PLA) treatments were applied before each trial. The three testing days were performed with a 72h interval apart. A single therapist was involved with the random allocation of the PBMT and PLA interventions. This therapist received instructions not to disclose the treatment modality employed during each assessment session to either the cyclists or other researchers involved with data collection and data analysis. Furthermore, cyclists utilized opaque eyewear to shield their eyes and obstruct their visual access (visual blinding) during the PBMT or PLA intervention. The therapist was explicitly advised against revealing the treatment modality to both the cyclists and the other researchers. PBMT did not elicit any thermal or tactile sensations, thereby ensuring that athletes remained unaware of the specific application on their thigh area. The random assignment was determined through a basic drawing of lots during the first testing session, determining the allocation of either active PBMT or inactive PLA.
PURPOSE:To obtain a cosmetic suitably useful for treating pimples, by blending a cosmetic base with immunoglobulin of bovine milk serum as an active ingredient. CONSTITUTION:Bovine milk serum part obtained by treating ordinary milk or healthy bovine with an enzyme and/or acid, removing precipitating casein form the milk is subjected to ion exchange, gel filtration, affinity chromatography or ultrafiltration with 100,000mol.wt. of elimination limit to remove low-molecular soluble salt, lactose, protein having tens thousands molecular weight, etc. The prepared immunoglobulin fraction is separated and concentrated to give immunoglobulin of bovine milk serum. A cosmetic is blended with the immunoglobulin as an active ingredient. The amount of the immunoglobulin in the cosmetic is preferably >=5wt% calculated as a solid substance.
Participants: Thirty-three young tennis players aged between 9 and 12 yrs were recruited in the study. The exclusion criteria included those (a) with soft tissue or bone problems affecting lower extremity, (b) who had acute inflammation affecting lower extremity region, (c) had scoliosis, (d) who had undergone any orthopedic surgery, (e) who had defined any pain or painful area at lower extremities and (f) who were obese (BMI\>30 kg/m2).

Assessments: Thermal analysis was done for risk of injury including both lower extremities. Quadriceps muscle was chosen from upper leg and gastro soleus muscle was chosen from lower leg region for thermal analysis. The thermo graphic assessment was performed by using FLIR E5 (FLIR Systems AB, Sweden) thermal camera in order to evaluate which muscles had the highest thermal activity while maintaining stable upright posture. The part of muscle with more activation (greater heat) was measured by the thermo graphic camera and the heat was recorded in centigrade. Each participant was thermo graphically evaluated in the same room (ambient temperature, 21°C) and participants were left for 10-20 minutes to 'acclimatize' to the thermographic imaging environment FLIR E5 Thermal Camera, with a resolution of 120 x 90 pixels was used for thermal imaging and the Color Palette iron was chosen for displaying the images. It is indicated that IR imaging may be a reliable and valid measure of treatment outcomes with clinical utility and sensitivity

The power analysis indicated that 33 participants for total were needed with 80 % power and a 5 % type 1 error. The power analysis of our study showed a power of 80% with tissue temperature as the primary outcome. The data were analyzed using statistical software (SPSS version 18, Inc., Chicago, IL, USA). All the statistical analyses were set a priori at an alpha level of p\<0.05. The tests for homogeneity (Levene's test) and normality (Shapiro-Wilk) were used to determine the appropriate statistical methods. According to the test results, nonparametric Friedman test was used for comparisons between baseline, first taping and last taping. Wilcoxon test was used for possible differences which may occur between taping applications in order to identify the application that provided the difference. Parametric test assumptions were not possible due to small sample size and inhomogeneous parameters.
The invention discloses a traditional Chinese medicine preparation for treating hepatitis B. The traditional Chinese medicine preparation for treating the hepatitis B is prepared from the following raw materials in parts by weight: 20-30 parts of Poria cocos, 20-30 parts of Polygonum aviculare, 20-30 parts of jasmine, 10-20 parts of Oldenlandia diffusa, 10-20 parts of Scutellaria baicalensis, 10-20 parts of Polygonum cuspidatum, 5-15 parts of folium mori, 5-15 parts of scorpio and 5-10 parts of liquorice. The traditional Chinese medicine preparation disclosed by the invention has the effects of clearing away heat and toxic materials and soothing liver and promoting diuresis, and is suitable for treating the viral hepatitis B. When the hepatitis B is treated, the traditional Chinese medicine preparation is orally taken twice a day, and the dosage is about 10g each time. The traditional Chinese medicine preparation disclosed by the invention is remarkable in curative effect on the hepatitis B. After the traditional Chinese medicine preparation is taken for one to two months, the hepatitis B can be converted into virus carrying from positive epatitis B surface antigen-hepatitis B e antigen-hepatitis B core antibody (HBsAg HBeAg HBcAb) generally. Through clinical verifications, the effective rate of the traditional Chinese medicine preparation reaches 93.8 percent. The traditional Chinese medicine preparation has the advantages that the effect is fast; the curative effect is exact; the effective rate is high; and a long-term effect is good.
The invention relates to self-foaming and/or mousse-type cosmetic or dermatological preparations containing the following: an emulsifier system consisting of a) at least one emulsifier A, selected from the group of wholly, partially or non-neutralised, branched and/or unbranched, saturated and/or unsaturated fatty acids comprising a chain length of between 10 and 40 carbon atoms, b) at least one emulsifier B, selected from the group of polyethoxylated fatty acid esters comprising a chain length of between 10 and 40 carbon atoms and an ethoxylation degree of between 5 and 100 and c) at least one coemulsifier C, selected from the group of saturated and/or unsaturated, branched and/or unbranched fatty alcohols comprising a chain length of between 10 and 40 carbon atoms. The preparations also contain up to 30 wt. %, (in relation to the total weight of the preparation), of a lipid phase, between 1 and 90 vol. %, (in relation to the total volume of the preparation), of at least one gas, selected from the group containing air, oxygen, nitrogen, helium, argon, laughing gas (N2O) and carbon dioxide (CO2), between 0.01 and 10 wt. % of one or more gel-forming agents, selected from the group of inorganic thickeners, one or more substances, selected from the group of organic hydrocolloids and between 0.01 and 10 wt. % of one or more particulate hydrophobic and/or hydrophobed and/or oil-absorbing solid substances.
Severe hypertriglyceridemia is a pathological condition caused by genetic factors alone or in combination with environmental factors, sometimes leading to acute pancreatitis (AP). In this study, exome sequencing and biochemical analyses were performed in 4 patients with hypertriglyceridemia complicated by obesity or diabetes with a history of AP or decreased post-heparin LPL mass. In a patient with a history of AP, SNP rs199953320 resulting in LMF1 nonsense mutation and APOE rs7412 causing apolipoprotein E2 were both found in heterozygous form. Three patients were homozygous for APOA5 rs2075291, and one was heterozygous. ELISA and Western blot analysis of the serum revealed the existence of apolipoprotein A-V in the lipoprotein-free fraction regardless of the presence or absence of rs2075291; furthermore, the molecular weight of apolipoprotein A-V was different depending on the class of lipoprotein or lipoprotein-free fraction. Lipidomics analysis showed increased serum levels of sphingomyelin and many classes of glycerophospholipid; however, when individual patients were compared, the degree of increase in each class of phospholipid among cases did not coincide with the increases seen in total cholesterol and triglycerides. Moreover, phosphatidylcholine, lysophosphatidylinositol, and sphingomyelin levels tended to be higher in patients who experienced AP than those who did not, suggesting that these phospholipids may contribute to the onset of AP. In summary, this study revealed a new disease-causing gene mutation in LMF1, confirmed an association between overlapping of multiple gene mutations and severe hypertriglyceridemia, and suggested that some classes of phospholipid may be involved in the pathogenesis of AP.
The present invention relates to methods for expansion of stem or progenitor cells. These methods rely on Asb-a polypeptides or nucleic acids to temporarily suppress differentiation of the cells, thus allowing proliferation and self-renewal of the stem or progenitor cells. Abs-a polypeptides and coding sequences define a class of polypeptides and nucleic acids that are both structurally and functionally highly conserved among vertebrates. Asb-a polypeptides contain 6 ankyrin repeats and a SOCS box that mediate the effect of the polypeptide on the regulation of specific subsets of genes involved in differentiation. The invention discloses various methods to increase the intracellular concentration of an Asb-a polypeptide for suppression of terminal differentiation of the stem or progenitor cells. The invention further relates to Asb-a polypeptides and nucleic acids, vectors and host cells for use in methods for their production and for use in the method for expansion of stem or progenitor cells, as well as to stem or progenitor cells containing exogenous Asb-a polypeptides and nucleic acids.
The subject of the present invention is a method for (a) diagnosing or predicting the risk of life-threatening exacerbations or adverse events or (b) prognosing the severity or (c) predicting or monitoring the success of a treatment or intervention in a patient infected with a coronavirus, said method comprising: -determining the level of pro-adrenomedullin (SEQ ID No. 31) or fragments thereof in a sample of bodily fluid of said patient, -comparing the level of said pro-adrenomedullin or fragments thereof with a predetermined threshold or a previous level of pro-adrenomedullin or fragments thereof, and-correlating the level of said pro-adrenomedullin or fragments thereof with the risk of said life threatening exacerbations or adverse events, or-correlating the level of said pro-adrenomedullin or fragments thereof with said severity, or-correlating the level of said pro-adrenomedullin or fragments thereof with the success of said treatment or intervention, wherein said pro-adrenomedullin or fragments thereof are selected from PAMP (SEQ ID No. 32), MR-proardm (ADM ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34). The subject of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment or intervention of a patient infected with a coronavirus.
Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
The present invention is related to an interactive and multimedia medical report system and method thereof. The system comprises a test unit, a marking unit, a database, and an electronic device. The test unit enables generation of an image file, wherein a predefined tag is established in the first position and a special tag is established in the second position. The database is connected to the marking unit and stores the medical report comprising the predefined and special tags, and at least one of the tags established in the image file. The electronic device comprises a processing unit, which makes connections with the database through the communication unit for retrieval of the medical report. The electronic device further comprises a display unit, which is configured to show the predefined tag and the special tag, and at least one of the tags of the image file. The present disclosure further provides an interactive multimedia method for medical report.
Domestication syndrome, selection pressure, and modern plant breeding programs have reduced the genetic diversity of the wheat germplasm. For the genetic gains of breeding programs to be sustainable, plant breeders require a diverse gene pool to select genes for resistance to biotic stress factors, tolerance to abiotic stress factors, and improved quality and yield components. Thus, old landraces, subspecies and wild ancestors are rich sources of genetic diversity that have not yet been fully exploited, and it is possible to utilize this diversity. Compared with durum wheat, tetraploid wheat subspecies have retained much greater genetic diversity despite genetic drift and various environmental influences, and the identification and utilization of this diversity can make a greater contribution to the genetic enrichment of wheat. In addition, using the pre-breeding method, the valuable left-behind alleles in the wheat gene pool can be re-introduced through hybridization and introgressive gene flow to create a sustainable opportunity for the genetic gain of wheat. This review provides some insights about the potential of tetraploid wheats in plant breeding and the genetic gains made by them in plant breeding across past decades, and gathers the known functional information on genes/QTLs, metabolites, traits and their direct involvement in wheat resistance/tolerance to biotic/abiotic stresses.
BACKGROUND: There are few studies related to Coronavirus Disease 2019 (COVID-19) on the prevalence and nature of pain symptoms after hospital discharge, especially in individuals who develop moderate to severe disease forms. Therefore, this study aimed to evaluate the presence of chronic pain in patients discharged after hospitalization for COVID-19, and the relationship between the presence of chronic pain and intensive care stay, demographics, and risk factors for the worst Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outcome.
METHODS: A cross-sectional observational study was carried out on patients with COVID-19 who recovered after hospitalization. Patients were recruited at the least 3 months after discharge and their hospital's health files were prospected. The variables evaluated were demographics, the severity of SARS-CoV-2 infection (considering the need for intensive care), and the presence of chronic pain. The results were shown in a descriptive manner, and multivariate analysis expressed as Odds Ratios (ORs) and respective Confidence Intervals (CIs) for the outcomes studied. Statistical significance was set at p < 0.05.
RESULTS: Of 242 individuals included, 77 (31.8%) reported chronic pain related to COVID-19, with no correlation with the severity of infection. Female sex and obesity were associated with a higher risk for chronic pain with ORs of 2.69 (Confidence Interval [95% CI 1.4 to 5.0]) and 3.02 (95% CI 1.5 to 5.9). The limbs were the most affected areas of the body.
CONCLUSION: Chronic pain is common among COVID-19 survivors treated in hospital environments. Female sex and obesity are risk factors for its occurrence.
The present invention discloses a health care product using a capsule to encapsulate matrimony vine powder and lyophiled power of royal jelly, and a preparation method thereof. The raw material comprises lyophiled power of royal jelly, and matrimony vine powder, and the weight proportion is from 1:1 to 5. The technologic procedures comprises: the matrimony vine powder is produced; the lyophiled power of royal jelly is produced; the matrimony vine powder and the lyophiled power of royal jelly are encapsulated with a capsule. In the working procedure of mixed encapsulation, the mixture of the lyophiled power of royal jelly and the matrimony vine powder is put in a centrifugal stirrer to be rotated at the speed of 5 to 25 turns / hour. After stirred for 1 to 3 hours, the mixture is put in a vacuum drying chamber, and is kept for 15 to 45 minutes. The mixture is taken out and is filled in a capsule of which the specification is 0.2 g/granule, and a finished product is prepared. The present invention can perfectly reserve the effective components of royal jelly and matrimony vine, better promote the metabolism of the human body, has strong health care and immunological function and better effect of tonifying the kidney for improving eyesight. The product is convenient to carry and eat, and has longer shelf life than single products.